Biogen Analysts Laud Fda Extension of Alzheimer’s Drug Evaluate

Biogen  (BIIB) – Get Report shares rose Friday as analysts reacted positively to the Food items and Drug Administration’s conclusion to lengthen by a few months the evaluate period of time for Biogen’s aducanumab Alzheimer’s cure.